Compare MSGM & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSGM | GDTC |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 12.4M |
| IPO Year | 2020 | 2021 |
| Metric | MSGM | GDTC |
|---|---|---|
| Price | $3.94 | $1.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 119.9K | 7.3K |
| Earning Date | 05-08-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 252.13 | N/A |
| EPS | ★ 1.43 | N/A |
| Revenue | ★ $741,000.00 | N/A |
| Revenue This Year | $69.73 | $5.37 |
| Revenue Next Year | $146.81 | N/A |
| P/E Ratio | $2.73 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $0.73 |
| 52 Week High | $5.78 | $3.68 |
| Indicator | MSGM | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 47.18 | 52.62 |
| Support Level | $2.78 | $0.97 |
| Resistance Level | $4.57 | $1.11 |
| Average True Range (ATR) | 0.31 | 0.05 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 15.56 | 66.24 |
Motorsport Games Inc is a motorsport network company that combines engaging video games with esports competitions and content for racing fans and gamers around the globe. The company has its reportable segments into the development and publishing of interactive racing video games, entertainment content and services, and the organization and facilitation of esports tournaments, competitions, and events for licensed racing games as well as on behalf of third-party video game racing series and other video game publishers. The majority of the revenue is earned from Gaming.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.